I. Introduction: A Year of Unprecedented Change
2026 represents a watershed moment for drug payment and access in China. In a single negotiation cycle, the National Healthcare Security Administration (NHSA) accomplished three things that had never been attempted before: it brought million-yuan CAR-T cell therapies into formal basic medical insurance negotiations, it launched the first synchronized negotiation between the basic medical insurance directory and a commercial insurance innovative drug directory, and it introduced an 8-year price protection mechanism for high-level innovative drugs.
For international patients considering treatment in China, these reforms are not abstract policy shifts. They directly affect the affordability, predictability, and accessibility of cutting-edge therapies โ including several that are available nowhere else in the world. This article provides a detailed, evidence-based analysis of each reform and its practical implications.
II. CAR-T at the Negotiating Table: Breaking the "300,000 Yuan Barrier"
On June 30, 2026, the NHSA published the preliminary review list for the 2026 basic medical insurance directory adjustment. Among 557 drugs that passed initial review, two CAR-T cell therapy products drew particular attention: Juvena Therapeutics' naxitamab (ๆบ็่พพยฎ) and JW Therapeutics' relma-cel (ๅ่ฏบ่พพยฎ). Both are priced above 1 million yuan per treatment course โ earning them the "million-yuan anti-cancer drug" label in Chinese media.
The significance lies in what happens next. Industry analysts note that for CAR-T to be included in basic medical insurance, the price would likely need to drop to the 300,000-yuan level โ a reduction exceeding 70% from current pricing.
Yet the NHSA has been careful not to frame this as a simple "price cut" negotiation. In a notable procedural innovation, CAR-T products were admitted into the basic insurance review process under a special provision: they had already been included in the 2025 commercial insurance innovative drug directory. This is the first time the medical insurance adjustment has created a dedicated application channel for mature commercial insurance innovative drugs.
III. The Dual-Track System: Basic Insurance + Commercial Insurance
The most structurally significant reform of 2026 is the first-ever synchronized negotiation between China's basic medical insurance directory and the commercial health insurance innovative drug directory (ๅไฟๅๆฐ่ฏ็ฎๅฝ). Twelve high-value innovative drugs entered the on-site price negotiation for the commercial insurance directory, with approximately ten companies participating.
The commercial insurance track was first piloted in 2025. In that initial cycle, 121 drugs passed form review, 24 participated in dedicated negotiations, and 19 were ultimately successful. By March 2026, these 19 drugs had been used 3,012 times nationwide, with total drug costs of 65.97 million yuan and an average cost per use of 21,902 yuan.
The 2026 commercial insurance negotiation at a glance:
| Metric | 2026 Data |
|---|---|
| Drugs submitted for commercial insurance directory | 62 |
| Passed form review | 58 |
| Entered on-site price negotiation | 12 |
| Companies participating | ~10 (including CARsgen, Hengrun Dasheng, Chongqing Precision Biotech, Sanofi, AstraZeneca, Belief BioMed) |
Notably, CARsgen's subsidiary KaiXing Life Sciences brought its satri-cel (่็ๅบๅฅฅไป่ต) โ the world's first CAR-T therapy for solid tumors โ to the commercial insurance negotiation table.
IV. The 8-Year Price Protection Mechanism
Perhaps the most consequential long-term reform is the introduction of an 8-year price protection period for innovative drugs.
Under the 2026 rules, drugs with high innovation levels and significant clinical value may set prices that reflect their high R&D investment and risk during the initial market period, and these prices will remain relatively stable for an extended period. Specifically, exclusive negotiated drugs that remain in the directory for 8 consecutive years transition to the routine directory โ meaning companies face no continuous price-cut pressure during this window.
This represents a philosophical shift in China's drug pricing policy. As one analysis observed, the era of "soul-crushing price cuts" โ epitomized by the 2021 negotiation that reduced Spinraza from approximately 700,000 yuan per injection to about 33,000 yuan โ is giving way to a more balanced approach that recognizes the need to sustain innovation while ensuring access.
For international patients, this matters because:
- Predictability: A stable pricing environment reduces uncertainty when planning treatment budgets.
- Innovation incentive: The protection period encourages companies to bring novel therapies to China earlier rather than delaying for other markets.
- Quality signal: The mechanism explicitly rewards drugs with "high innovation levels and significant clinical value" โ the same criteria that international patients would use to evaluate treatment options.
V. Practical Takeaways for International Patients
| Reform | What It Means for You |
|---|---|
| CAR-T enters basic insurance negotiation | If successful, may establish a lower reference price; current self-pay cost remains ~$80,000โ$120,000 |
| Dual-track commercial insurance | Creates a transparent pricing pathway for high-value therapies; 19 drugs already covered in 2025 cycle |
| 8-year price protection | Reduces pricing volatility; signals that China will remain a competitive market for innovative therapies |
VI. Conclusion
China's 2026 payment reform represents a maturation of its approach to drug access. Rather than relying solely on aggressive price negotiation, the NHSA has built a multi-layered architecture: basic insurance for broad access, commercial insurance for high-value therapies, and price protection to sustain innovation. For international patients, this means a more predictable, transparent, and innovation-friendly environment for accessing cutting-edge treatments in China.